Edwards Lifesciences reported better-than-expected fourth-quarter sales, driven by its transcatheter aortic valve replacement (TAVR) devices, to finish 2024 on an upbeat but cautious note after a ...

Edwards Lifesciences Corp.’s posted fourth quarter results slightly ahead of expectations, but indicated that the first quarter of 2025 might not be as bright. The company expects growth for both its ...

Stifel analyst Rick Wise upgraded Edwards from Hold to Buy, raising the price forecast to $90 from $75. Wise suggests that recent conversations with six Transcatheter aortic valve replacement ...

which reflects the continuation of softer demand for TAVR in 2025. While Edwards is expected to receive a substantial indication expansion for its Sapien 3 valve in mid-2025, we doubt this will ...

Stifel analyst Rick Wise upgraded Edwards from Hold to Buy, raising the price forecast to $90 from $75. Wise suggests that recent conversations with six Transcatheter aortic valve replacement (TAVR) ...

Why it matters: Edwards reached an inflection point in 2024 with transcatheter aortic valve, or TAVR, sales slowing, while the launch of and revenue from new transcatheter mitral and tricuspid ...

The TAVR market, which has been a key driver of Edwards Lifesciences' growth in recent years, is facing a period of moderation. The company has reported a slowdown in TAVR sales, attributing this ...

Looking ahead, Edwards Lifesciences has provided guidance for 2024, projecting operational revenue growth of 8-10% year-over-year. This forecast, while positive, represents a downward revision from ...